Washington, D.C – The Medical Imaging & Technology Alliance (MITA) – the leading trade association representing the manufacturers of medical imaging equipment, radiopharmaceuticals, contrast media, and focused ultrasound therapeutic devices – has submitted comments to the Office of the United States Trade Representative (USTR) regarding extending tariff exclusions for certain medical products needed to address the continuing COVID-19 pandemic and encouraging USTR to reconsider additional exemptions.
“During this ongoing public health emergency, we continue to see the value of medical imaging by an increased demand for technologies used to diagnose, treat and monitor patients with COVID-19,” said Patrick Hope, Executive Director, MITA. “While we applauded the recently announced continuation of China 301 tariff exemptions for medical devices, more can be done to ensure key manufacturing components are readily available and not subject to onerous tariffs as we address this evolving crisis.”
In its comments, MITA advocated that the USTR continue exempting China 301 tariff exclusions, including certain ultrasonic scanning apparatuses, bismuth germane crystals used in PET imaging, MRI enclosure devices, combined PET/CT scanners, X-ray parts including tables and tube housing as well as data input devices and monitors.
“MITA looks forward to continued work with the USTR to ensure access and availability of essential imaging devices necessary to care for Americans facing COVID-19,” Hope concluded.
MITA’s full comments are available here.
MITA is the collective voice of manufacturers of medical imaging equipment, radiopharmaceuticals, contrast media, and focused ultrasound therapeutic devices. It represents companies whose sales comprise more than 90 percent of the global market for medical imaging innovations. These products include: magnetic resonance imaging (MRI), medical X-Ray equipment, computed tomography (CT) scanners, ultrasound, nuclear imaging, radiopharmaceuticals, and imaging information systems. MITA Member company technologies are an important part of our nation’s healthcare infrastructure and are essential for the screening, diagnosis, staging, managing and effectively treating patients with cancer, heart disease, neurological degeneration, and numerous other medical conditions.